Pharvaris (PHVS) Reports 83% Lower HAE Attack Rate Versus Placebo
Pharvaris (PHVS) reported that its drug deucrictibant XR reduced HAE attack rates by 83% versus placebo in a Phase 3 trial. The trial met all primary and secondary endpoints, with 45% of participants attack-free over 24 weeks. No serious adverse events were reported.
How this was made

The 30-second read
Why it matters
The data represent a material clinical milestone that could accelerate regulatory filings and market adoption.
Market read
First report of pivotal trial results; likely to move PHVS stock and influence the HAE therapeutic space.
What to watch
Potential safety concerns long‑term and pricing/reimbursement challenges.
Background
Pharvaris released Phase 3 data for its HAE prophylaxis candidate deucrictibant XR, showing an 83% reduction in attack rate.
Ticker impact
Phase 3 CHAPTER-3 trial shows deucrictibant XR cuts HAE attack rate by 83% versus placebo.
upward pressure as market prices in the efficacy breakthrough.
First disclosure of statistically significant Phase 3 results; biotech stocks typically react strongly to such news.
Market effects
Strengthens the hereditary angioedema therapeutic segment and may boost related biotech peers.
US biotech market sees fresh catalyst.
Moderate, as HAE treatments have worldwide demand.
Counterpoint
Efficacy may not translate into commercial success if regulatory hurdles or competition arise.
Key entities
- companyPharvaris
Biotech firm developing deucrictibant XR for hereditary angioedema.
